The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients

Biochemical Pharmacology

Volumn 83, Issue 7, 2012, Pages 903-908

  Namazi, Soha ^a,d   Kojuri, Javad ^b,d   Khalili, Andia ^a,d   Azarpira, Negar ^c,d  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d NONE

Author keywords

Clopidogrel; CYP2C19 polymorphism; CYP3A5 polymorphism; P2Y12 polymorphism; Post stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 3A5; PURINERGIC P2Y12 RECEPTOR;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DEMOGRAPHY; DRUG RESPONSE; ENVIRONMENTAL FACTOR; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; IRAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PERCUTANEOUS CORONARY INTERVENTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THROMBOCYTE AGGREGATION; TURBIDIMETRY;

ARYL HYDROCARBON HYDROXYLASES; BLOOD PLATELETS; CATHETER ABLATION; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP3A; DRUG-ELUTING STENTS; FEMALE; HUMANS; IRAN; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, PURINERGIC P2Y12; THROMBOSIS; TICLOPIDINE;

EID: 84857373777     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.01.003     Document Type: Article

References (63)

1. S.R. Mehta, S. Yusuf, R.J. Peters, M.E. Bertrand, B.S. Lewis, and M.K. Natarajan Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533
2. S.R. Steinhubl, P.B. Berger, J.T. Mann, E.T.A. Fry, A. DeLago, and C. Wilmer CREDO Investigators. Clopidogrel for the Reduction of Events during Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial (CREDO) J Am Med Assoc 288 2002 2411 2420
3. T.A. Nguyen, J.G. Diodati, and C. Pharand Resistance to clopidogrel: a review of the evidence J Am Coll Cardiol 45 2005 1157 1164
4. A.A. Barsky, and R.R. Arora Clopidogrel resistance: myth or reality J Cardiovasc Pharmacol Ther 11 2006 47 53
5. E. Camilleri, L. Jacquin, F. Paganelli, and L. Bonello Personalized antiplatelet therapy: review of the latest clinical evidence Curr Cardiol Rep 13 2011 296 302
6. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, and T.A. Bass Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 2007 1505 1516
7. D. Sibbing, and A. Kastrati Risk of combining PPIs with thienopyridines: fact or fiction Lancet 374 2009 952 954
8. G. Campo, M. Miccoli, M. Tebaldi, J. Marchesini, L. Fileti, and M. Monti Genetic determinants of on-clopidogrel high platelet reactivity Platelets 22 2011 399 407
9. T.A. Clarke, and L.A. Waskell The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin Drug Metab Dispos 31 2003 53 59
10. Antiplatelet Drug Clopidogrel Pathway (PK). http://www.pharmgkb.org/ search/pathway/platelet/platelet-clopidogrel-pk.jsp [accessed 20.11.09].
11. P. Kuehl, J. Zhang, Y. Lin, J. Lamba, M. Assem, and J. Schuetz Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat Genet 27 2001 383 391
12. W.E. Evans, and H.L. McLeod Pharmacogenomics - drug disposition, drug targets, and side effects N Engl J Med 348 2003 538 549
13. H.G. Xie, A.J. Wood, R.B. Kim, C.M. Stein, and G.R. Wilkinson Genetic variability in CYP3A5 and its possible consequences Pharmacogenomics 5 2004 243 272
14. C. Balram, Q. Zhou, Y.B. Cheung, and E.J. Lee CYP3A5*3 and*6 single nucleotide polymorphisms in three distinct Asian populations Eur J Clin Pharmacol 59 2003 123 126
15. Y. Jounaïdi, V. Hyrailles, L. Gervot, and P. Maurel Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein Biochem Biophys Res Commun 221 1996 466 470
16. R.H. van Schaik, I.P. van der Heiden, J.N. van den Anker, and J. Lindemans CYP3A5 variant allele frequencies in Dutch Caucasians Clin Chem 48 2002 1668 1671
17. S.R. Steinhubl Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines Circulation 121 2010 481 483
18. H. Chen, W. Yan, and X.Y. Wu Relationships of blood stasis syndrome, CYP2C19 gene polymorphism with clopidogrel resistance and post-PCI prognosis Zhongguo Zhong Xi Yi Jie He Za Zhi 30 2010 1245 1249
19. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, and J.T. Brandt Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
20. A.A. Pettersen, H. Arnesen, T.B. Opstad, and I. Seljeflot The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel Thromb J 9 2011 4
21. Y.H. Jeong, I.S. Kim, Y. Park, M.K. Kang, J.S. Koh, and S.J. Hwang Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study JACC Cardiovasc Interv 3 2010 731 741
22. D. Sibbing, W. Koch, D. Gebhard, T. Schuster, S. Braun, and J. Stegherr Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement Circulation 121 2010 512 518
23. M. Cattaneo Platelet P2 receptors: old and new targets for antithrombotic drugs Expert Rev Cardiovasc Ther 5 2007 45 55
24. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramírez, U. Cavallari, and E. Trabetti Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease Thromb Res 116 2005 491 497
25. P. Fontana, A. Dupont, S. Gandrille, C. Bachelot-Loza, J.L. Reny, and M. Aiach Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects Circulation 108 2003 989 995
26. E.I. Lev, R.T. Patel, S. Guthikonda, D. Lopez, P.F. Bray, and N.S. Kleiman Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel Thromb Res 119 2007 355 360
27. J.W. Suh, B.K. Koo, S.Y. Zhang, K.W. Park, J.Y. Cho, and I.J. Jang Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel CMAJ 174 2006 1715 1722
28. K.A. Kim, P.W. Park, and J.Y. Park Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects Eur J Clin Pharmacol 64 2008 589 597
29. D. Trenk, W. Hochholzer, M.F. Fromm, L.E. Chialda, A. Pahl, and C.M. Valina Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 51 2008 1925 1934
30. J.M. Lee, S. Park, D.J. Shin, D. Choi, C.Y. Shim, and Y.G. Ko Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans Am J Cardiol 104 2009 46 51
31. S. Farjadian, M. Ota, H. Inoko, and A. Ghaderi The genetic relationship among Iranian ethnic groups: an anthropological view based on HLA class II gene polymorphism Mole Biol Rep 36 2009 1943 1950
32. C.F. Lacy, L.L. Armstrong, M.P. Goldman, and L.A. Lance Drug information handbook 19th ed. 2010-2011 Lexi-comp, Inc Hudson, Ohio
33. E. Thervet, D. Anglicheau, B. King, M.H. Schlageter, B. Cassinat, and P. Beaune Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients Transplantation 76 2003 1233 1235
34. J.K. Lamba, R.K. Dhiman, and K.K. Kohli CYP2C19 genetic mutations in North Indians Clin Pharmacol Ther 68 2000 328 335
35. I. Müller, F. Besta, C. Schulz, S. Massberg, A. Schönig, and M. Gawaz Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement Thromb Haemost 89 2003 783 787
36. W.M. Samara, K.P. Bliden, U.S. Tantry, and P.A. Gurbel The difference between clopidogrel responsiveness and posttreatment platelet reactivity Thromb Res 115 2005 89 94
37. P.A. Gurbel, K.P. Bliden, B.L. Hiatt, and C.M. O'Connor Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913
38. E.I. Lev, R.T. Patel, K.J. Maresh, S. Guthikonda, J. Granada, and T. DeLao Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance J Am Coll Cardiol 47 2006 27 33
39. M. Rozalski, M. Boncler, B. Luzak, and C. Watala Genetic factors underlying differential blood platelet sensitivity to inhibitors Pharmacol Rep 57 2005 1 13
40. T. Cuisset, C. Frere, J. Quilici, P.E. Morange, N. Saut, and M. Lambert Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome Thromb Res 120 2007 893 899
41. P. Fontana, P. Gaussem, M. Aiach, J.N. Fiessinger, J. Emmerich, and J.L. Reny P2Y12 H2 Haplotype is associated with peripheral arterial disease: a case-control study Circulation 108 2003 2971 2973
42. C. Frere, T. Cuisset, P.E. Morange, J. Quilici, L. Camoin-Jau, and N. Saut Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome Am J Cardiol 101 2008 1088 1093
43. N. Azarpira, S. Namazi, A. Khalili, and M. Tabesh The investigation of allele and genotype frequencies of CYP3A5 (1*/3*) and P2Y12 (T744C) in Iran Mol Biol Rep 2010
44. K. Yamamoto, S. Hokimoto, T. Chitose, K. Morita, T. Ono, and K. Kaikita Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy J Cardiol 57 2011 194 201
45. T. Sawada, T. Shinke, J. Shite, T. Honjo, Y. Haraguchi, and R. Nishio Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel Circ J 75 2010 99 105
46. X.L. Liu, Z.J. Wang, Q. Yang, H.L. Ge, F. Gao, and Y.Y. Liu Impact of CYP2C19 polymorphism and smoking on response to clopidogrel in patients with stable coronary artery disease Chin Med J 123 2010 3178 3183
47. I.Y. Oh, K.W. Park, S.H. Kang, J.J. Park, S.H. Na, and H.J. Kang Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents Heart 2011
48. S.J. Hwang, Y.H. Jeong, I.S. Kim, J.S. Koh, M.K. Kang, and Y. Park The cytochrome 2C19*2 and*3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention Thromb Res 127 2011 23 28
49. F. Sofi, B. Giusti, R. Marcucci, A.M. Gori, R. Abbate, and G.F. Gensini Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis Pharmacogenomics J 11 2011 199 206
50. D. Sibbing, J. Stegherr, W. Latz, W. Koch, J. Mehilli, and K. Dorrler Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention Eur Heart J 30 2009 916 922
51. L. Bonello, S. Armero, O. Ait Mokhtar, J. Mancini, P. Aldebert, and N. Saut Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism J Am Coll Cardiol 56 2010 1630 1636
52. J.P. Collet, J.S. Hulot, A. Pena, E. Villard, J.B. Esteve, and J. Silvain Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
53. A.R. Shuldiner, J.R. O'Connell, K.P. Bliden, A. Gandhi, K. Ryan, and R.B. Horenstein Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy J Am Med Assoc 302 2009 849 857
54. T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, and N. Meneveau French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
55. J.L. Mega, T. Simon, J.P. Collet, J.L. Anderson, E.M. Antman, and K. Bliden Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis J Am Med Assoc 304 2010 1821 1830
56. L. Wallentin, S. James, R.F. Storey, M. Armstrong, B.J. Barratt, and J. Horrow PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial Lancet 376 2010 1320 1328
57. G. Pare, S.R. Mehta, S. Yusuf, S.S. Anand, S.J. Connolly, and J. Hirsh Effects of CYP2C19 genotype on outcomes of clopidogrel treatment N Engl J Med 363 2010 1704 1714
58. S.M.G. Smith, R. Buckland, M.E. Daly, and R.F. Storey Inhibition of platelet aggregation by clopidogrel is unaffected by the CYP2C19 681G>A polymorphism in patients with coronary artery disease (abstr) J Am Coll Cardiol 49 2007 375A
59. Z. Desta, X. Zhao, J.G. Shin, and D.A. Flockhart Clinical significance of the cytochrome P450 2C19 genetic polymorphism Clin Pharmacokinet 41 2002 913 958
60. H.G. Xie, R.B. Kim, A.J. Wood, and C.M. Stein Molecular basis of ethnic differences in drug disposition and response Annu Rev Pharmacol Toxicol 41 2001 815 850
61. P.J. Wedlund The CYP2C19 enzyme polymorphism Pharmacology 61 2000 174 183
62. N. Azarpira, S. Namazi, F. Hendijani, M. Banan, and M. Darai Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran Pharmacol Rep 62 2010 740 746
63. N. Zand, N. Tajik, A.S. Moghaddam, and I. Milanian Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population Clin Exp Pharmacol Physiol 34 2007 102 105